Loading JAZZ detail
Loading ticker data...
Loading JAZZ detail
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc.
Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Chart data unavailable
Aaron Wealth Advisors LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,979 shares of the specialty pharmaceutical company's stock, valued at approximately $506,000. Several other hedge funds and
Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real-world evidence addressing rare neurological disorders, including rare and severe forms of epilepsy andsleep disorders For U.S. media and investors only DUBLIN, April 9, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago. The research demonstrates the breadth of Jazz's neuroscience portfolio spanning epilepsy and sleep disorders, with new clinical data evaluating Epidiolex ® (cannabidiol) in patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC), or other refractory epilepsies; and Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy.
Capricorn Fund Managers Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the specialty pharmaceutical company's stock, valued at approximately $1,700,000. A number of other institutional investors also
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director directly owned 384,682 shares of
DUBLIN, April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness CHICAGO, March 24, 2026 /PRNewswire/ -- The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with these conditions, and empower them to feel confident, informed, and supported in their nutritional and health choices.
Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally activated IFN ⍺2b cytokine For U.S. media and investors only DUBLIN, March 18, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company and its partners will present one oral and six poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego. The research highlights meaningful progress across Jazz's oncology portfolio, including new findings from company-sponsored research evaluating Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody; JZP898, an investigational, differentiated, conditionally activated interferon alpha-2b (IFN⍺2b) cytokine pro-drug designed for activation within the tumor microenvironment; and imipridone compounds including Modeyso™ (dordaviprone), a protease activator of the mitochondrial caseinolytic protease P (ClpP) and a dopamine D2 receptor (DRD2) inhibitor.
Shares of Jazz Pharmaceuticals plc are consolidating below record highs after a bull-flag breakout, with tightening price action suggesting a potential breakout from a multi-year base.
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Crossmark Global Holdings Inc. lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 74.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,674 shares of the specialty pharmaceutical company's stock after selling 10,433 shares during the quarter.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Examine Jazz's (JAZZ) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Jazz Pharmaceuticals JAZZ has reached a milestone that most conventional cannabis players are yet to achieve — generating sustained, billion-dollar revenues from a cannabis product.
